VSIR and neoplasm: During tumor therapy, blockade of VISTA boosted recruitment of tumor-specific T cells and activated DCs in the tumor microenvironment, while decreasing the number and activity of myeloid derived suppressor cells and tumor-specific Treg cells [525,526].